Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Selectis Health (GBCS) Other Non-Current Assets (2017 - 2025)

Selectis Health's Other Non-Current Assets history spans 11 years, with the latest figure at $842061.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $842061.0 for Q4 2025, up 18.33% from a year ago — trailing twelve months through Dec 2025 was $842061.0 (up 18.33% YoY), and the annual figure for FY2025 was $842061.0, up 18.33%.
  • Other Non-Current Assets for Q4 2025 was $842061.0 at Selectis Health, up from $806886.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.1 million in Q3 2023 to a low of $711634.0 in Q4 2024.
  • The 5-year median for Other Non-Current Assets is $838223.0 (2024), against an average of $871729.9.
  • The sharpest move saw Other Non-Current Assets surged 107.77% in 2021, then fell 26.39% in 2024.
  • Year by year, Other Non-Current Assets stood at $853656.0 in 2021, then increased by 16.72% to $996400.0 in 2022, then dropped by 17.69% to $820124.0 in 2023, then fell by 13.23% to $711634.0 in 2024, then grew by 18.33% to $842061.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $842061.0, $806886.0, and $771940.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.